{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:44Z","timestamp":1790958584025,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Research Conventional Grant from Gabrielle\u2019s Angel Foundation and Mark Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1038\/s41375-022-01774-z","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:00:48Z","timestamp":1669899648000},"page":"396-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-5973","authenticated-orcid":false,"given":"Wei","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2731-6091","authenticated-orcid":false,"given":"Masahiro","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3333-0490","authenticated-orcid":false,"given":"Subin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall E.","family":"Kadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8602-6054","authenticated-orcid":false,"given":"Masao","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9948-8696","authenticated-orcid":false,"given":"Yibin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"1774_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/jcp.50.2.128","volume":"50","author":"D Wright","year":"1997","unstructured":"Wright D, McKeever P, Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children\u2019s Cancer Study Group. J Clin Pathol. 1997;50:128\u201334.","journal-title":"J Clin Pathol"},{"key":"1774_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2141.2005.05735.x","volume":"131","author":"B Burkhardt","year":"2005","unstructured":"Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131:39\u201349.","journal-title":"Br J Haematol"},{"key":"1774_CR3","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/ijc.21716","volume":"118","author":"A Brauninger","year":"2006","unstructured":"Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin\u2019s and Reed\/Sternberg cells in Hodgkin\u2019s lymphoma. Int J Cancer. 2006;118:1853\u201361.","journal-title":"Int J Cancer"},{"key":"1774_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"G Egger","year":"2004","unstructured":"Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457\u201363.","journal-title":"Nature"},{"key":"1774_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMra1112635","volume":"367","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N. Engl J Med. 2012;367:647\u201357.","journal-title":"N. Engl J Med"},{"key":"1774_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0092-8674(00)82001-2","volume":"87","author":"VV Ogryzko","year":"1996","unstructured":"Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87:953\u20139.","journal-title":"Cell"},{"key":"1774_CR7","doi-asserted-by":"crossref","unstructured":"Attar N, Kurdistani SK. Exploitation of EP300 and CREBBP lysine acetyltransferases by cancer. Cold Spring Harb Perspect Med. 2017;7:a026534.","DOI":"10.1101\/cshperspect.a026534"},{"key":"1774_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature09730","volume":"471","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189\u201395.","journal-title":"Nature"},{"key":"1774_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298\u2013303.","journal-title":"Nature"},{"key":"1774_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/2159-8290.CD-15-0754","volume":"6","author":"H Ogiwara","year":"2016","unstructured":"Ogiwara H, Sasaki M, Mitachi T, Oike T, Higuchi S, Tominaga Y, et al. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Disco. 2016;6:430\u201345.","journal-title":"Cancer Disco"},{"key":"1774_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","volume":"51","author":"SN Meyer","year":"2019","unstructured":"Meyer SN, Scuoppo C, Vlasevska S, Bal E, Holmes AB, Holloman M, et al. Unique and Shared Epigenetic Programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma. Immunity. 2019;51:535\u201347.","journal-title":"Immunity"},{"key":"1774_CR12","doi-asserted-by":"crossref","unstructured":"Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9:2024.","DOI":"10.1038\/s41467-018-04356-9"},{"key":"1774_CR13","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41375-020-01093-1","volume":"35","author":"C Lobello","year":"2021","unstructured":"Lobello C, Tichy B, Bystry V, Radova L, Filip D, Mraz M, et al. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. Leukemia. 2021;35:1500\u20135.","journal-title":"Leukemia"},{"key":"1774_CR14","doi-asserted-by":"publisher","first-page":"111386","DOI":"10.18632\/oncotarget.22799","volume":"8","author":"E Mata","year":"2017","unstructured":"Mata E, Diaz-Lopez A, Martin-Moreno AM, Sanchez-Beato M, Varela I, Mestre MJ, et al. Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. Oncotarget. 2017;8:111386\u201395.","journal-title":"Oncotarget"},{"key":"1774_CR15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","volume":"131","author":"E Tiacci","year":"2018","unstructured":"Tiacci E, Ladewig E, Schiavoni G, Penson A, Fortini E, Pettirossi V, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018;131:2454\u201365.","journal-title":"Blood"},{"key":"1774_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0195-7","volume":"9","author":"E Mata","year":"2019","unstructured":"Mata E, Fernandez S, Astudillo A, Fernandez R, Garcia-Cosio M, Sanchez-Beato M, et al. Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. Blood Cancer J. 2019;9:34.","journal-title":"Blood Cancer J"},{"key":"1774_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2019001043","volume":"134","author":"JP Zhang","year":"2019","unstructured":"Zhang JP, Song Z, Wang HB, Lang L, Yang YZ, Xiao W, et al. A novel model of controlling PD-L1 expression in ALK(+) anaplastic large cell lymphoma revealed by CRISPR screening. Blood. 2019;134:171\u201385.","journal-title":"Blood"},{"key":"1774_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.0303-6987.2006.00548.x","volume":"33","author":"W Kempf","year":"2006","unstructured":"Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol. 2006;33:58\u201370.","journal-title":"J Cutan Pathol"},{"key":"1774_CR19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3324\/haematol.2009.008250","volume":"94","author":"B Falini","year":"2009","unstructured":"Falini B, Martelli MP. Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica. 2009;94:897\u2013900.","journal-title":"Haematologica"},{"key":"1774_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nature24028","volume":"550","author":"LM Lasko","year":"2017","unstructured":"Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, et al. Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours. Nature. 2017;550:128\u201332.","journal-title":"Nature"},{"key":"1774_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1021\/acsmedchemlett.6b00075","volume":"7","author":"AM Taylor","year":"2016","unstructured":"Taylor AM, Cote A, Hewitt MC, Pastor R, Leblanc Y, Nasveschuk CG, et al. Fragment-based discovery of a selective and cell-active benzodiazepinone CBP\/EP300 bromodomain inhibitor (CPI-637). ACS Med Chem Lett. 2016;7:531\u20136.","journal-title":"ACS Med Chem Lett"},{"key":"1774_CR22","first-page":"1567","volume":"9","author":"M Shiota","year":"1994","unstructured":"Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene. 1994;9:1567\u201374.","journal-title":"Oncogene"},{"key":"1774_CR23","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/sj.onc.1201062","volume":"14","author":"SW Morris","year":"1997","unstructured":"Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin\u2019s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14:2175\u201388.","journal-title":"Oncogene"},{"key":"1774_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2291","volume":"8","author":"R Chiarle","year":"2008","unstructured":"Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11\u201323.","journal-title":"Nat Rev Cancer"},{"key":"1774_CR25","doi-asserted-by":"crossref","unstructured":"Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci. 2020;21:1102.","DOI":"10.3390\/ijms21031102"},{"key":"1774_CR26","doi-asserted-by":"crossref","unstructured":"Wang YC, Nowakowski GS, Wang ML, Ansell SM. Advances in CD30-and PD-1-targeted therapies for classical Hodgkin lymphoma. J Hematol Oncol. 2018;11:57.","DOI":"10.1186\/s13045-018-0601-9"},{"key":"1774_CR27","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","volume":"96","author":"H Stein","year":"2000","unstructured":"Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681\u201395.","journal-title":"Blood"},{"key":"1774_CR28","doi-asserted-by":"crossref","unstructured":"Wei W, Lin Y, Song Z, Xiao W, Chen L, Yin J, et al. A20 and RBX1 regulate brentuximab vedotin sensitivity in hodgkin lymphoma models. Clin Cancer Res. 2020;16:4093\u20134106.","DOI":"10.1158\/1078-0432.CCR-19-4137"},{"key":"1774_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1182\/blood-2014-08-594507","volume":"125","author":"A Weilemann","year":"2015","unstructured":"Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, et al. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood. 2015;125:124\u201332.","journal-title":"Blood"},{"key":"1774_CR30","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1182\/blood-2014-05-578575","volume":"125","author":"RL Boddicker","year":"2015","unstructured":"Boddicker RL, Kip NS, Xing X, Zeng Y, Yang ZZ, Lee JH, et al. The oncogenic transcription factor IRF4 is regulated by a novel CD30\/NF-kappaB positive feedback loop in peripheral T-cell lymphoma. Blood. 2015;125:3118\u201327.","journal-title":"Blood"},{"key":"1774_CR31","doi-asserted-by":"crossref","unstructured":"Bandini C, Pupuleku A, Spaccarotella E, Pellegrino E, Wang R, Vitale N, et al. IRF4 mediates the oncogenic effects of STAT3 in anaplastic large cell lymphomas. Cancers (Basel). 2018;10:21.","DOI":"10.3390\/cancers10010021"},{"key":"1774_CR32","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41375-018-0045-9","volume":"32","author":"N Schleussner","year":"2018","unstructured":"Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, et al. The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17\/ILC3 skewing of anaplastic large cell lymphoma. Leukemia. 2018;32:1994\u20132007.","journal-title":"Leukemia"},{"key":"1774_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","volume":"39","author":"MA Weniger","year":"2016","unstructured":"Weniger MA, Kuppers R. NF-kappaB deregulation in Hodgkin lymphoma. Semin Cancer Biol. 2016;39:32\u20139.","journal-title":"Semin Cancer Biol"},{"key":"1774_CR34","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2018-08-871293","volume":"133","author":"L von Hoff","year":"2019","unstructured":"von Hoff L, Kargel E, Franke V, McShane E, Schulz-Beiss KW, Patone G, et al. Autocrine LTA signaling drives NF-kappaB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma. Blood. 2019;133:1489\u201394.","journal-title":"Blood"},{"key":"1774_CR35","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O\u2019Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268\u201377.","journal-title":"Blood"},{"key":"1774_CR36","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34:2690\u20137.","journal-title":"J Clin Oncol"},{"key":"1774_CR37","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O\u2019Donnell E, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18:1611\u20138.","journal-title":"Clin Cancer Res"},{"key":"1774_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.","journal-title":"Nature"},{"key":"1774_CR39","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","volume":"35","author":"MA Weniger","year":"2021","unstructured":"Weniger MA, Kuppers R. Molecular biology of Hodgkin lymphoma. Leukemia. 2021;35:968\u201381.","journal-title":"Leukemia"},{"key":"1774_CR40","doi-asserted-by":"crossref","unstructured":"Mao W, Ghasemzadeh A, Freeman ZT, Obradovic A, Chaimowitz MG, Nirschl TR, et al. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition. J Immunother Cancer. 2019;7:277.","DOI":"10.1186\/s40425-019-0758-y"},{"key":"1774_CR41","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/cbin.11139","volume":"43","author":"KS Liu","year":"2019","unstructured":"Liu KS, Zhou ZF, Gao HY, Yang F, Qian YJ, Jin HT, et al. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression. Cell Biol Int. 2019;43:642\u201350.","journal-title":"Cell Biol Int"},{"key":"1774_CR42","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41388-020-1270-z","volume":"39","author":"J Liu","year":"2020","unstructured":"Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, et al. p300\/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer. Oncogene. 2020;39:3939\u201351.","journal-title":"Oncogene"},{"key":"1774_CR43","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1158\/0008-5472.CAN-15-0236","volume":"75","author":"S Picaud","year":"2015","unstructured":"Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, et al. Generation of a selective small molecule inhibitor of the CBP\/p300 bromodomain for leukemia therapy. Cancer Res. 2015;75:5106\u201319.","journal-title":"Cancer Res"},{"key":"1774_CR44","doi-asserted-by":"crossref","unstructured":"Conery AR, Centore RC, Neiss A, Keller PJ, Joshi S, Spillane KL, et al. Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife. 2016;5:e10483.","DOI":"10.7554\/eLife.10483"},{"key":"1774_CR45","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/1541-7786.MCR-18-0719","volume":"17","author":"V Garcia-Carpizo","year":"2019","unstructured":"Garcia-Carpizo V, Ruiz-Llorente S, Sarmentero J, Gonzalez-Corpas A, Barrero MJ. CREBBP\/EP300 bromodomain inhibition affects the proliferation of AR-positive breast cancer cell lines. Mol Cancer Res. 2019;17:720\u201330.","journal-title":"Mol Cancer Res"},{"key":"1774_CR46","doi-asserted-by":"publisher","first-page":"10549","DOI":"10.1021\/acs.jmedchem.6b01022","volume":"59","author":"TD Crawford","year":"2016","unstructured":"Crawford TD, Romero FA, Lai KW, Tsui V, Taylor AM, de Leon Boenig G, et al. Discovery of a potent and selective in vivo probe (GNE-272) for the bromodomains of CBP\/EP300. J Med Chem. 2016;59:10549\u201363.","journal-title":"J Med Chem"},{"key":"1774_CR47","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1182\/bloodadvances.2020001879","volume":"4","author":"F Spriano","year":"2020","unstructured":"Spriano F, Gaudio E, Cascione L, Tarantelli C, Melle F, Motta G, et al. Antitumor activity of the dual BET and CBP\/EP300 inhibitor NEO2734. Blood Adv. 2020;4:4124\u201335.","journal-title":"Blood Adv"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01774-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01774-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01774-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T11:08:44Z","timestamp":1675422524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01774-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1774"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01774-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}